Table 2.
Diagnosis and schedule of chemotherapy among the patients evaluated for anthracycline-induced cardiotoxicity
| Diagnosis | Patients. (n=160) | Regimen | Schedule | Cycles received |
| Breast cancer | 110 (68.8%) | CA†F | 3 weekly | 6 (4–6) |
| NHL | 21(13.1%) | CHOP | 3 weekly | 3 (2–6) |
| HD | 09 (5.6%) | A†BVD | 2 weekly | 3 (2–6) |
| AML | 04 (2.5%) | Dauno/AraC | Daily | 3 (3–5) |
| ALL | 01 (0.6%) | DVPA‡ | Daily | 3 (3–3) |
| HCC | 06 (3.7%) | Doxorubicin | Weekly | 6 (3–6) |
| Sarcomas | 06 (3.7%) | A†D | 3 weekly | 6 (0–6) |
Note: A† – Adriamycin/(Doxorubicin/Hydroxydaunorubicin[H]), A‡ - L –Asparaginase, AraC – Cytarabine, B –Bleomycin, C – Cyclophosphamide, D – Dacarbazine, F - %-Fluorouracil, O – Oncovin/(Vincristine[V]), P – Prednisone, H –/(Adriamycin/Doxorubicin)